0000891532 false --12-31 Q1 PERMA FIX ENVIRONMENTAL SERVICES INC. 0000891532 2022-01-01 2022-03-31 0000891532 2022-05-04 0000891532 2022-03-31 0000891532 2021-12-31 0000891532 2021-01-01 2021-03-31 0000891532 us-gaap:CommonStockMember 2021-12-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000891532 us-gaap:TreasuryStockMember 2021-12-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000891532 us-gaap:NoncontrollingInterestMember 2021-12-31 0000891532 us-gaap:RetainedEarningsMember 2021-12-31 0000891532 us-gaap:CommonStockMember 2020-12-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0000891532 us-gaap:TreasuryStockMember 2020-12-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000891532 us-gaap:NoncontrollingInterestMember 2020-12-31 0000891532 us-gaap:RetainedEarningsMember 2020-12-31 0000891532 2020-12-31 0000891532 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0000891532 us-gaap:TreasuryStockMember 2022-01-01 2022-03-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0000891532 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-03-31 0000891532 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0000891532 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0000891532 us-gaap:TreasuryStockMember 2021-01-01 2021-03-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0000891532 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0000891532 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0000891532 us-gaap:CommonStockMember 2022-03-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0000891532 us-gaap:TreasuryStockMember 2022-03-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0000891532 us-gaap:NoncontrollingInterestMember 2022-03-31 0000891532 us-gaap:RetainedEarningsMember 2022-03-31 0000891532 us-gaap:CommonStockMember 2021-03-31 0000891532 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0000891532 us-gaap:TreasuryStockMember 2021-03-31 0000891532 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0000891532 us-gaap:NoncontrollingInterestMember 2021-03-31 0000891532 us-gaap:RetainedEarningsMember 2021-03-31 0000891532 2021-03-31 0000891532 PESI:PFMPolandMember 2021-01-01 2021-12-31 0000891532 PESI:FixedPriceMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:FixedPriceMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:FixedPriceMember 2022-01-01 2022-03-31 0000891532 PESI:FixedPriceMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:FixedPriceMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:FixedPriceMember 2021-01-01 2021-03-31 0000891532 PESI:TimeandMaterialsMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:TimeandMaterialsMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:TimeandMaterialsMember 2022-01-01 2022-03-31 0000891532 PESI:TimeandMaterialsMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:TimeandMaterialsMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:TimeandMaterialsMember 2021-01-01 2021-03-31 0000891532 PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticGovernmentMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticGovernmentMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticGovernmentMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticGovernmentMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticGovernmentMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticGovernmentMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticCommercialMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticCommercialMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticCommercialMember 2022-01-01 2022-03-31 0000891532 PESI:DomesticCommercialMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticCommercialMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:DomesticCommercialMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignGovernmentMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignGovernmentMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignGovernmentMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignGovernmentMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignGovernmentMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignGovernmentMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignCommercialMember PESI:TreatmentMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignCommercialMember PESI:ServicesMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignCommercialMember 2022-01-01 2022-03-31 0000891532 PESI:ForeignCommercialMember PESI:TreatmentMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignCommercialMember PESI:ServicesMember 2021-01-01 2021-03-31 0000891532 PESI:ForeignCommercialMember 2021-01-01 2021-03-31 0000891532 PESI:YearToDateChangesMember 2022-01-01 2022-03-31 0000891532 us-gaap:PatentsMember 2022-01-01 2022-03-31 0000891532 us-gaap:PatentsMember 2022-03-31 0000891532 us-gaap:PatentsMember 2021-12-31 0000891532 PESI:SoftwareMember 2022-01-01 2022-03-31 0000891532 PESI:SoftwareMember 2022-03-31 0000891532 PESI:SoftwareMember 2021-12-31 0000891532 us-gaap:CustomerRelationshipsMember 2022-01-01 2022-03-31 0000891532 us-gaap:CustomerRelationshipsMember 2022-03-31 0000891532 us-gaap:CustomerRelationshipsMember 2021-12-31 0000891532 PESI:TwoThousandAndSeventeenStockOptionPlanMember PESI:ConsultantMember 2017-07-26 2017-07-27 0000891532 PESI:FergusonStockOptionMember PESI:SecondMilestoneMember 2017-07-26 2017-07-27 0000891532 PESI:FergusonStockOptionMember PESI:ThirdMilestoneMember 2017-07-26 2017-07-27 0000891532 PESI:RobertFergusonMember 2022-03-31 0000891532 PESI:EmployeeAndDirectorsMember 2022-03-31 0000891532 PESI:EmployeeAndDirectorsMember 2022-01-01 2022-03-31 0000891532 PESI:TwoThousandThreeOutsideDirectorsStockOptionPlanMember us-gaap:CommonStockMember 2022-01-01 2022-03-31 0000891532 PESI:TwoThousandTwentyManagementIncentivePlanMember 2022-01-01 2022-03-31 0000891532 PESI:RobertFergusonMember 2019-04-02 0000891532 PESI:RobertFergusonMember 2019-03-30 2019-04-02 0000891532 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0000891532 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0000891532 PESI:DirectorStockOptionsMember 2022-01-01 2022-03-31 0000891532 PESI:DirectorStockOptionsMember 2021-01-01 2021-03-31 0000891532 us-gaap:StockOptionMember 2021-12-31 0000891532 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0000891532 us-gaap:StockOptionMember 2022-03-31 0000891532 us-gaap:StockOptionMember 2020-12-31 0000891532 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0000891532 us-gaap:StockOptionMember 2021-03-31 0000891532 PESI:StockOptionOutstandingMember 2022-01-01 2022-03-31 0000891532 PESI:StockOptionExercisableMember 2022-01-01 2022-03-31 0000891532 PESI:RevolvingCreditMember 2020-05-07 2020-05-08 0000891532 PESI:RevolvingCreditMember 2022-03-31 0000891532 PESI:TermLoanMember 2020-05-07 2020-05-08 0000891532 PESI:TermLoanMember 2022-03-31 0000891532 PESI:NotePayableOneMember 2022-03-31 0000891532 PESI:NotePayableTwoMember 2022-03-31 0000891532 PESI:RevolvingCreditMember 2022-03-31 0000891532 PESI:RevolvingCreditMember 2021-12-31 0000891532 PESI:TermLoanMember 2022-03-31 0000891532 PESI:TermLoanMember 2021-12-31 0000891532 PESI:NotePayableMember 2022-03-31 0000891532 PESI:NotePayableMember 2021-12-31 0000891532 us-gaap:RevolvingCreditFacilityMember PESI:RevisedLoanAgreementMember PESI:PNCBankMember 2020-05-06 2020-05-08 0000891532 us-gaap:RevolvingCreditFacilityMember PESI:RevisedLoanAgreementMember PESI:PNCBankMember 2020-05-08 0000891532 PESI:RevisedLoanAgreementMember PESI:PNCBankMember PESI:TermLoanMember 2020-05-08 0000891532 PESI:RevisedLoanAgreementMember PESI:PNCBankMember PESI:TermLoanMember 2020-05-06 2020-05-08 0000891532 2021-05-04 0000891532 srt:MinimumMember 2022-03-27 2022-03-29 0000891532 srt:MaximumMember 2022-03-27 2022-03-29 0000891532 2022-03-27 2022-03-29 0000891532 PESI:LenderMember 2022-03-29 0000891532 PESI:LoanAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:PrimeRateMember 2022-01-01 2022-03-31 0000891532 PESI:LoanAgreementMember us-gaap:RevolvingCreditFacilityMember 2022-01-01 2022-03-31 0000891532 PESI:LoanAgreementMember us-gaap:RevolvingCreditFacilityMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0000891532 PESI:LoanAgreementMember PESI:CapitalExpenditureMember us-gaap:PrimeRateMember 2022-01-01 2022-03-31 0000891532 PESI:LoanAgreementMember PESI:CapitalExpenditureMember us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0000891532 us-gaap:LondonInterbankOfferedRateLIBORMember 2022-01-01 2022-03-31 0000891532 us-gaap:RevolvingCreditFacilityMember 2022-03-31 0000891532 PESI:CanadianNuclearLaboratoriesLTDMember 2022-01-01 2022-03-31 0000891532 PESI:CanadianNuclearLaboratoriesLTDMember 2022-03-31 0000891532 PESI:AmericanInternationalGroupIncMember 2003-06-01 2003-06-30 0000891532 PESI:AmericanInternationalGroupIncMember 2022-03-31 0000891532 PESI:AmericanInternationalGroupIncMember PESI:ThousandandThreeClosurePolicyMember 2022-03-31 0000891532 PESI:AmericanInternationalGroupIncMember PESI:ThousandandThreeClosurePolicyMember 2021-12-31 0000891532 PESI:AmericanInternationalGroupIncMember PESI:ThousandandThreeClosurePolicyMember 2022-01-01 2022-03-31 0000891532 PESI:AmericanInternationalGroupIncMember PESI:ThousandandThreeClosurePolicyMember 2021-01-01 2021-12-31 0000891532 PESI:AmericanInternationalGroupIncMember 2022-01-01 2022-03-31 0000891532 PESI:AmericanInternationalGroupIncMember 2021-01-01 2021-03-31 0000891532 2021-01-01 2021-12-31 0000891532 PESI:SegmentsTotalMember 2022-01-01 2022-03-31 0000891532 us-gaap:CorporateAndOtherMember 2022-01-01 2022-03-31 0000891532 PESI:MedicalMember 2021-01-01 2021-03-31 0000891532 PESI:SegmentsTotalMember 2021-01-01 2021-03-31 0000891532 us-gaap:CorporateAndOtherMember 2021-01-01 2021-03-31 0000891532 PESI:EngineeringRemediationResourcesGroupIncMember 2022-01-01 2022-03-31 0000891532 PESI:PermaFixERRGMember 2022-03-31 0000891532 srt:ExecutiveOfficerMember 2022-01-01 2022-03-31 0000891532 PESI:CEOMember 2022-01-19 2022-01-20 0000891532 PESI:CEOMember 2022-01-20 0000891532 srt:ChiefFinancialOfficerMember 2022-01-19 2022-01-20 0000891532 srt:ChiefFinancialOfficerMember 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfStrategicInitiativesMember 2022-01-19 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfStrategicInitiativesMember 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfNuclearAndTechnicalServicesMember 2022-01-19 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfNuclearAndTechnicalServicesMember 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfWasteTreatmentOperationsMember 2022-01-19 2022-01-20 0000891532 PESI:ExecutiveVicePresidentOfWasteTreatmentOperationsMember 2022-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure PESI:Integer iso4217:CAD

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

Form 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended March 31, 2022

 

Or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from   to  

 

Commission File No. 1-11596

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction

of incorporation or organization)

58-1954497

(IRS Employer

Identification Number)

   

8302 Dunwoody Place, Suite 250, Atlanta, GA

(Address of principal executive offices)

30350

(Zip Code)

   

(770) 587-9898

(Registrant’s telephone number)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol   Name of each exchange on which registered
Common Stock, $.001 Par Value   PESI   NASDAQ Capital Markets

 

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files).

Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ☐ Accelerated Filer ☒ Non-accelerated Filer ☐ Smaller reporting company Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial standards provided pursuant to Section 13(a) of the Exchange Act ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Indicate the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the close of the latest practical date.

 

Class   Outstanding at May 4, 2022
Common Stock, $.001 Par Value   13,256,097 shares

 

 

 

 
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

 

INDEX

 

Page No.
PART I FINANCIAL INFORMATION  
  Item 1. Consolidated Financial Statements 1
    Consolidated Balance Sheets -March 31, 2022 and December 31, 2021 1
    Consolidated Statements of Operations -Three Months Ended March 31, 2022 and 2021 3
    Consolidated Statements of Comprehensive Loss -Three Months Ended March 31, 2022 and 2021 4
    Consolidated Statements of Stockholders’ Equity -Three Months Ended March 31, 2022 and 2021 5
    Consolidated Statements of Cash Flows -Three Months Ended March 31, 2022 and 2021 6
    Notes to Consolidated Financial Statements 7
  Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 21
  Item 3. Quantitative and Qualitative Disclosures About Market Risk 32
  Item 4. Controls and Procedures 32
       
PART II OTHER INFORMATION  
  Item 1. Legal Proceedings 33
  Item 1A. Risk Factors 33
  Item 6. Exhibits 34

 

 
 

 

PART I - FINANCIAL INFORMATION

 

Item 1. – Financial Statements

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets

 

   March 31,   December 31, 
   2022   2021 
(Amounts in Thousands, Except for Share and Per Share Amounts)  (Unaudited)   (Audited) 
         
ASSETS          
Current assets:          
Cash  $3,925   $4,440 
Accounts receivable, net of allowance for doubtful accounts of $26 and $85, respectively   10,322    11,372 
Unbilled receivables   5,275    8,995 
Inventories   953    680 
Prepaid and other assets   4,077    4,472 
Current assets related to discontinued operations   27    15 
Total current assets   24,579    29,974 
           
Property and equipment:          
Buildings and land   20,642    20,631 
Equipment   22,531    22,131 
Vehicles   449    443 
Leasehold improvements   23    23 
Office furniture and equipment   1,316    1,316 
Construction-in-progress   2,849    2,997 
Total property and equipment   47,810    47,541 
Less accumulated depreciation   (29,167)   (28,932)
Net property and equipment   18,643    18,609 
           
Property and equipment related to discontinued operations   81    81 
           
Operating lease right-of-use assets   2,347    2,460 
           
Intangibles and other long term assets:          
Permits   9,486    9,476 
Other intangible assets - net   852    894 
Finite risk sinking fund (restricted cash)   11,482    11,471 
Deferred tax assets   4,263    3,527 
Other assets   443    809 
Total assets  $72,176   $77,301 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

1
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Balance Sheets, Continued

 

   March 31,   December 31 
   2022   2021 
(Amounts in Thousands, Except for Share and per Share Amounts)  (Unaudited)   (Audited) 
         
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Accounts payable  $10,329   $11,975 
Accrued expenses   5,537    5,078 
Disposal/transportation accrual   1,162    1,065 
Deferred revenue   2,707    5,580 
Accrued closure costs - current   547    578 
Current portion of long-term debt   384    393 
Current portion of operating lease liabilities   416    406 
Current portion of finance lease liabilities   354    333 
Current liabilities related to discontinued operations   802    506 
Total current liabilities   22,238    25,914 
           
Accrued closure costs   6,706    6,613 
Long-term debt, less current portion   491    600 
Long-term operating lease liabilities, less current portion   1,921    2,029 
Long-term finance lease liabilities, less current portion   920    884 
Long-term liabilities related to discontinued operations   408    677 
Total long-term liabilities   10,446    10,803 
           
Total liabilities   32,684    36,717 
           
Commitments and Contingencies (Note 9 )        
           
Stockholders’ Equity:          
Preferred Stock, $.001 par value; 2,000,000 shares authorized, no shares issued and outstanding        
Common Stock, $.001 par value; 30,000,000 shares authorized; 13,242,072 and 13,222,552 shares issued, respectively; 13,234,430 and 13,214,910 shares outstanding, respectively   13    13 
Additional paid-in capital   114,532    114,307 
Accumulated deficit   (74,963)   (73,620)
Accumulated other comprehensive loss   (2)   (28)
Less Common Stock in treasury, at cost; 7,642 shares   (88)   (88)
Total stockholders’ equity   39,492    40,584 
           
Total liabilities and stockholders’ equity  $72,176   $77,301 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Operations

(Unaudited)

 

(Amounts in Thousands, Except for Per Share Amounts)  2022   2021 
  

Three Months Ended

March 31,

 
(Amounts in Thousands, Except for Per Share Amounts)  2022   2021 
         
Revenues  $15,915   $23,133 
Cost of goods sold   14,279    20,777 
Gross profit   1,636    2,356 
           
Selling, general and administrative expenses   3,422    3,205 
Research and development   96    150 
Loss on disposal of property and equipment   1     
Loss from operations   (1,883)   (999)
           
Other income (expense):          
Interest income   11    18 
Interest expense   (35)   (67)
Interest expense-financing fees   (13)   (8)
Other   (2)   1 
Loss from continuing operations before taxes   (1,922)   (1,055)
Income tax benefit   (673)   (17)
Loss from continuing operations, net of taxes   (1,249)   (1,038)
           
Loss from discontinued operations (net of taxes) (Note 10)   (94)   (115)
Net loss   (1,343)   (1,153)
           
Net loss attributable to non-controlling interest       (30)
           
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders  $(1,343)  $(1,123)
           
Net loss per common share attributable to Perma-Fix Environmental Services, Inc. stockholders - basic and diluted:          
Continuing operations  $(.09)  $(.08)
Discontinued operations   (.01)   (.01)
Net loss per common share  $(.10)  $(.09)
           
Number of common shares used in computing net loss per share:          
Basic   13,234    12,165 
Diluted   13,234    12,165 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

3
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Comprehensive Loss

(Unaudited)

 

(Amounts in Thousands)  2022   2021 
  

Three Months Ended

March 31,

 
(Amounts in Thousands)  2022   2021 
         
Net loss  $(1,343)  $(1,153)
Other comprehensive income:          
Foreign currency translation gain   26    20 
Total other comprehensive income   26    20 
           
Comprehensive loss   (1,317)   (1,133)
Comprehensive loss attributable to non-controlling interest       (30)
Comprehensive loss attributable to Perma-Fix Environmental Services, Inc. stockholders  $(1,317)  $(1,103)

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

4
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC

Consolidated Statement of Stockholders’ Equity

(Unaudited)

(Amounts in thousands, except for share amounts)

 

   Shares   Amount   Capital   Treasury   Loss   Subsidiary   Deficit   Equity 
   Common Stock   Additional Paid-In   Common Stock Held In   Accumulated Other Comprehensive   Non-controlling Interest in   Accumulated   Total Stockholders’ 
   Shares   Amount   Capital   Treasury   Loss   Subsidiary   Deficit   Equity 
                                 
Balance at December 31, 2021   13,222,552   $13   $114,307   $(88)  $(28)  $   $(73,620)  $40,584 
Net loss                           (1,343)   (1,343)
Foreign currency translation                   26            26 
Issuance of Common Stock for services   19,520        123                    123 
Stock-Based Compensation           102                    102 
Balance at March 31, 2022   13,242,072   $13   $114,532   $(88)  $(2)  $    $(74,963)  $39,492 
                                         
Balance at December 31, 2020   12,161,539   $12   $108,931   $(88)  $(207)  $(1,742)  $(74,455)  $32,451 
Net loss                       (30)   (1,123)   (1,153)
Foreign currency translation                   20            20 
Issuance of Common Stock for services   11,837        79                                 79 
Stock-Based Compensation           45                    45 
Balance at March 31, 2021   12,173,376   $12   $109,055   $(88)  $(187)  $(1,772)  $(75,578)  $31,442 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

5
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Consolidated Statements of Cash Flows

(Unaudited)

 

(Amounts in Thousands)  2022   2021 
   Three Months Ended 
   March 31,
(Amounts in Thousands)  2022   2021 
Cash flows from operating activities:          
Net loss  $(1,343)  $(1,153)
Less: loss from discontinued operations, net of taxes (Note 10)   (94)   (115)
           
Loss from continuing operations, net of taxes   (1,249)   (1,038)
Adjustments to reconcile loss from continuing operations to cash provided by (used in) operating activities :          
Depreciation and amortization   456    400 
Interest on finance lease with purchase option       2 
Amortization of debt issuance costs   13    8 
Deferred tax benefit   (673)    
Recovery of bad debt reserves   (55)   (17)
Loss on disposal of plant, property, and equipment   1     
Issuance of common stock for services   123    79 
Stock-based compensation   102    45 
Changes in operating assets and liabilities of continuing operations:          
Accounts receivable   1,105    (10,445)
Unbilled receivables   3,720    5,224 
Prepaid expenses, inventories and other assets   1,097    557 
Accounts payable, accrued expenses and unearned revenue   (4,492)   (1,270)
Cash provided by (used in) continuing operations   148    (6,455)
Cash used in discontinued operations   (142)   (149)
Cash provided by (used in) operating activities   6    (6,604)
           
Cash flows from investing activities:          
Purchases of property and equipment   (345)   (361)
Proceeds from sale of plant, property, and equipment   24    1 
Cash used in investing activities of continuing operations   (321)   (360)
           
Cash flows from financing activities:          
Repayments of revolving credit borrowings   (17,494)   (14,780)
Borrowing on revolving credit   17,494    14,780 
Principal repayments of finance lease liabilities   (58)   (114)
Principal repayments of long term debt   (110)   (109)
Payment of debt issuance costs   (21)    
Cash used in financing activities   (189)   (223)
           
Effect of exchange rate changes on cash       (6)
           
(Decrease) increase in cash and finite risk sinking fund (restricted cash)   (504)   (7,193)
Cash and finite risk sinking fund (restricted cash) at beginning of period   15,911    19,370 
Cash and finite risk sinking fund (restricted cash) at end of period  $15,407   $12,177 
           
Supplemental disclosure:          
Interest paid  $34   $54 
Income taxes paid   6     
Non-cash investing and financing activities:          
Equipment purchase subject to finance lease   114     
Equipment purchase subject to financing       29 

 

The accompanying notes are an integral part of these condensed consolidated financial statements.

 

6
 

 

PERMA-FIX ENVIRONMENTAL SERVICES, INC.

Notes to Consolidated Financial Statements

 

March 31, 2022

(Unaudited)

 

Reference is made herein to the notes to consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.

 

1. Basis of Presentation

 

The consolidated financial statements included herein have been prepared by the Company (which may be referred to as we, us or our), without an audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“the Commission”). Certain information and note disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although the Company believes the disclosures which are made are adequate to make the information presented not misleading. Further, the consolidated financial statements reflect, in the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position and results of operations as of and for the periods indicated. The results of operations for the three months ended March 31, 2022 are not necessarily indicative of results to be expected for the fiscal year ending December 31, 2022.

 

The Company suggests that these consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021.

 

The consolidated financial statements include the accounts of our wholly-owned subsidiaries and the account of a variable interest entity (“VIE”), Perma-Fix ERRG for which we are the primary beneficiary (See “Note 13 - VIE” for a discussion of this VIE). The consolidated financial statements for 2021 also included the accounts of the Company’s majority-owned Polish subsidiary, Perma-Fix Medical S.A (“PFM Poland”) and PFM Poland’s wholly-owned subsidiary, Perma-Fix Medical Corporation (“PFMC”), which comprised of the Company’s Medical Segment. As previously discussed, the Company made the strategic decision to cease all research and development (“R&D”) activities under the Medical Segment and sold 100% of its interest in PFM Poland in December 2021. As a condition precent to the sale of PFM Poland, the Company acquired PFMC after its conversion to a Delaware limited liability company. As a result of the sale of PFM Poland, the Company deconsolidated PFM Poland from its consolidated financial statements in December 2021. The Company’s Medical Segment had not generated any revenue.

 

Information for the Medical Segment is presented for the quarter ending March 31, 2021. The Medical Segment was disposed of as of December 31, 2021 and is not relevant for the quarter ending March 31, 2022. Prior period segment information is not required to be restated for the disposal of the segment.

 

2. Summary of Significant Accounting Policies

 

Our accounting policies are as set forth in the notes to the December 31, 2021 consolidated financial statements referred to above.

 

7
 

 

Recently Adopted Accounting Standards

 

In May 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2021-04, “Earnings Per Share (Topic 206), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40): Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force).” ASU 2021-04 addresses issuer’s accounting for certain modifications or exchanges of freestanding equity-classified written call options. This ASU is effective for all entities, for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Early adoption is permitted. The adoption of this ASU by the Company effective January 1, 2022 did not have a material impact on its financial statements.

 

Recently Issued Accounting Standards – Not Yet Adopted

 

In June 2016, the FASB issued ASU No. 2016-13, “Credit Losses (Topic 326) - Measurement of Credit Losses on Financial Instruments,” and various subsequent amendments to the initial guidance (collectively, “Topic 326”). Topic 326 introduces an approach, based on expected losses, to estimate credit losses on certain types of financial instruments and modifies the impairment model for available-for-sale debt securities. The new approach to estimating credit losses (referred to as the current expected credit losses model) applies to most financial assets measured at amortized cost and certain other instruments, including trade and other receivables and loans. Entities are required to apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is adopted. In November 2019, FASB issued ASU 2019-10, “Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842),” which defers the effective date of ASU 2016-13 for public companies that are considered smaller reporting companies (“SRC”) as defined by the Commission to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. These ASUs are effective January 1, 2023 for the Company as an SRC. Under new guidance issued by the Commission in March 2020, the Company continues to qualify as a smaller reporting company but became an accelerated filer starting with its 2021 Form 10-K and all subsequent filings. The Company is currently evaluating the impact of these ASU on its consolidated financial statements.

 

In March 2020, the FASB issued ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” which provides optional expedients and exceptions for applying U.S. GAAP to contracts, hedging relationships and other transactions affected by the discontinuation of the London Interbank Offered Rate (“LIBOR”) or by another reference rate expected to be discontinued because of reference rate reform. The guidance was effective beginning March 12, 2020 and can be applied prospectively through December 31, 2022. In January 2021, the FASB issued ASU No. 2021-01, “Reference Rate Reform (Topic 848): Scope,” which clarified the scope and application of the original guidance. The Company plans to adopt both ASUs when LIBOR is discontinued. The Company is currently evaluating the impact of the new ASUs on its condensed consolidated financial statements. As of the date of this report, the Company has determined that only its obligations under the credit facility as described in “Note 8 – Long Term Debt would be impacted by these ASUs. The Company’s obligations under its credit facility permit for payment of annual rate of interests on its obligations using prime rate or LIBOR.

 

In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments by removing major separation models and removing certain settlement condition qualifiers for the derivatives scope exception for contracts in an entity’s own equity, and simplifies the related diluted net income per share calculation for both Subtopics. ASU 2020-06 is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2023, for the Company as an SRC. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently evaluating the impact of this ASU on its consolidated financial statements and disclosures.

 

8
 

 

3. Revenue

 

Disaggregation of Revenue

 

In general, the Company’s business segmentation is aligned according to the nature and economic characteristics of our services and provides meaningful disaggregation of each business segment’s results of operations. The nature of the Company’s performance obligations within our Treatment and Services Segments results in the recognition of our revenue primarily over time. The following tables present further disaggregation of our revenues by different categories for our Services and Treatment Segments:

 

Revenue by Contract Type                        
(In thousands)  Three Months Ended   Three Months Ended 
   March 31, 2022   March 31, 2021 
   Treatment   Services   Total   Treatment   Services   Total 
Fixed price  $7,479   $5,761   $13,240   $7,495   $2,581   $10,076 
Time and materials       2,675    2,675        13,057    13,057 
Total  $7,479   $8,436   $15,915   $7,495   $15,638   $23,133 

 

Revenue by generator                        
(In thousands)  Three Months Ended   Three Months Ended 
   March 31, 2022   March 31, 2021 
   Treatment   Services   Total   Treatment   Services   Total 
Domestic government  $5,815   $8,245   $14,060   $4,598   $12,661   $17,259 
Domestic commercial   1,436    162    1,598    2,265    590    2,855 
Foreign government   92    6    98    534    2,364    2,898 
Foreign commercial   136    23    159    98    23    121 
Total  $7,479   $8,436   $15,915   $7,495   $15,638   $23,133 

 

Contract Liabilities

 

The Company’s contract liabilities consist of deferred revenues which represent advance payment from customers in advance of the completion of our performance obligation. The following table represents changes in our contract liabilities balances:

 

           Year-to-date   Year-to-date 
(In thousands)  March 31, 2022   December 31, 2021   Change ($)   Change (%) 
Contract liabilities                    
Deferred revenue  $2,707   $5,580   $(2,873)   (51.5)%

 

The decrease was primarily due to revenue recognized in connection with a Services Segment contract. The decrease was also attributed to more processing of Treatment Segment’s backlog due to continued delays in waste receipts from certain customers from the impact of COVID-19.

 

During the three months ended March 31, 2022 and 2021, the Company recognized revenue of $3,521,000 and $4,311,000, respectively, related to untreated waste that was in the Company’s control as of the beginning of each respective year. Revenue recognized in each period related to performance obligations satisfied within the respective period.

 

Remaining Performance Obligations

 

The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one year or less.

 

Within our Services Segment, there are service contracts which provide that the Company has a right to consideration from a customer in an amount that corresponds directly with the value to the customer of our performance completed to date. For those contracts, the Company has utilized the practical expedient in ASC 606-10-55-18, which allows the Company to recognize revenue in the amount for which we have the right to invoice; accordingly, the Company does not disclose the value of remaining performance obligations for those contracts.

 

The Company’s contracts and subcontracts relating to activities at governmental sites generally allow for termination for convenience at any time at the government’s option without payment of a substantial penalty. The Company does not disclose remaining performance obligations on these contracts.

 

9
 

 

4. Leases

 

At the inception of an arrangement, the Company determines if an arrangement is, or contains, a lease based on facts and circumstances present in that arrangement. Lease classifications, recognition, and measurement are then determined at the lease commencement date.

 

The Company’s operating lease right-of-use (“ROU”) assets and operating lease liabilities represent primarily leases for office and warehouse spaces used to conduct our business. Finance leases consist primarily of processing and transport equipment used by our facilities’ operations.

 

The components of lease cost for the Company’s leases were as follows (in thousands):

 

   2022   2021 
   Three Months Ended 
   March 31, 
   2022   2021 
Operating Lease:          
Lease cost  $157   $111 
           
Finance Leases:          
Amortization of ROU assets   47    59 
Interest on lease liability   11    19 
Finance leases   58    78 
           
Short-term lease rent expense   3    3 
           
Total lease cost  $218   $192 

 

The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2022 were:

 

   Operating Leases   Finance Leases 
Weighted average remaining lease terms (years)   6.7    4.0 
           
Weighted average discount rate   7.6%   6.1%

 

The weighted average remaining lease term and the weighted average discount rate for operating and finance leases at March 31, 2021 were:

 

   Operating Leases   Finance Leases 
Weighted average remaining lease terms (years)   7.8    3.4 
           
Weighted average discount rate   7.8%   6.8%

 

10
 

 

The following table reconciles the undiscounted cash flows for the operating and finance leases at March 31, 2022 to the operating and finance lease liabilities recorded on the balance sheet (in thousands):

 

   Operating Leases   Finance Leases 
2022 (Remaining)  $433   $315 
2023   560    327 
2024   419    323 
2025   328    300 
2026   304    171 
2027 and thereafter   955    20 
Total undiscounted lease payments   2,999    1,456 
Less: Imputed interest   (662)   (182)
Present value of lease payments  $2,337   $1,274 
           
Current portion of operating lease obligations  $416   $ 
Long-term operating lease obligations, less current portion  $1,921   $ 
Current portion of finance lease obligations  $   $354 
Long-term finance lease obligations, less current portion  $   $920 

 

Supplemental cash flow and other information related to our leases were as follows (in thousands):

 

   2022   2021 
   Three Months Ended 
   March 31, 
   2022   2021 
Cash paid for amounts included in the measurement of lease liabilities:        
Operating cash flow from operating leases  $143   $101 
Operating cash flow from finance leases  $11   $19 
Financing cash flow from finance leases  $58   $114 
           
ROU assets obtained in exchange for lease obligations for:          
Finance liabilities  $147   $ 
Operating liabilities  $    $  

 

 

5. Intangible Assets

 

The following table summarizes information relating to the Company’s definite-lived intangible assets:

 

       March 31, 2022   December 31, 2021 
  

Weighted Average

Amortization

   Gross       Net   Gross       Net 
   Period   Carrying   Accumulated   Carrying   Carrying   Accumulated   Carrying 
   (Years)   Amount   Amortization   Amount   Amount   Amortization   Amount 
Other Intangibles (amount in thousands)                            
Patent   8.3   $787   $(354)  $433   $787   $(351)  $436 
Software   3    606    (428)   178    592    (415)   177 
Customer relationships   10    3,370    (3,129)   241    3,370    (3,089)   281 
Total       $4,763   $(3,911)  $852   $4,749   $(3,855)  $894 

 

The intangible assets noted above are amortized on a straight-line basis over their useful lives with the exception of customer relationships which are being amortized using an accelerated method.

 

11
 

 

The following table summarizes the expected amortization over the next five years for our definite-lived intangible assets:

 

   Amount 
Year  (In thousands) 
      
2022 (Remaining)  $164 
2023   178 
2024   46 
2025   11 
2026   11 

 

Amortization expenses relating to the definite-lived intangible assets as discussed above were $56,000 and $50,000 for the three months ended March 31, 2022 and 2021, respectively.

 

6. Capital Stock, Stock Plans, Warrants and Stock Based Compensation

 

The Company has certain stock option plans under which it may award incentive stock options (“ISOs”) and/or non-qualified stock options (“NQSOs”) to employees, officers, outside directors, and outside consultants. No stock options were granted in the first quarter of 2022.

 

The Company granted a NQSO to Robert Ferguson on July 27, 2017 from the Company’s 2017 Stock Option Plan (“2017 Plan”) for the purchase of up to 100,000 shares of the Company’s Common Stock (“Ferguson Stock Option”) in connection with his work as a consultant to the Company’s Test Bed Initiative (“TBI”) at our Perma-Fix Northwest Richland, Inc. (“PFNWR”) facility at an exercise price of $3.65 per share, which was the fair market value of the Company’s Common Stock on the date of grant. The term of the Ferguson Stock Option is seven years from the grant date. The vesting of the Ferguson Stock Option is subject to the achievement of three separate milestones by certain dates. The first milestone was met and the shares under the first milestone were issued to Robert Ferguson in May 2018. The Company had previously entered into amendments whereby the vesting dates for the second and third milestones for the purchase of up to 30,000 and 60,000 shares of the Company’s Common Stock were extended to December 31, 2021 and December 31, 2022, respectively. On January 20, 2022, the Company’s Compensation and Stock Option Committee (“Compensation Committee”) and the Board of Directors (“Board”) further amended the vesting dates of the second and third milestones to December 31, 2022 and December 31, 2023, respectively. This amendment was approved by the Compensation Committee and the Board to take effect December 31, 2021. The Company has not recognized compensation costs (fair value of approximately $289,000 at March 31, 2022) for the remaining 90,000 Ferguson Stock Option under the remaining two milestones since achievement of the performance obligation under each of the two remaining milestones is uncertain at March 31, 2022. All other terms of the Ferguson Stock Option remain unchanged.

 

The following table summarizes stock-based compensation recognized for the three months ended March 31, 2022 and 2021 for our employee and director stock options.

 Schedule of Share-based Compensation, Allocation of Recognized Period Costs

     2022 2021 
   Three Months Ended 
Stock Options  March 31, 
   2022   2021 
Employee Stock Options  $86,000   $33,000 
Director Stock Options   16,000    12,000 
Total  $102,000   $45,000 

 

At March 31, 2022, the Company has approximately $1,287,000 of total unrecognized compensation costs related to unvested options for employee and directors. The weighted average period over which the unrecognized compensation costs are expected to be recognized is approximately 4.1 years.

 

12
 

 

The summary of the Company’s total Stock Option Plans as of March 31, 2022 and March 31, 2021, and changes during the periods then ended, are presented below. The Company’s Plans consist of the 2010 Stock Option Plan, the 2017 Plan and the 2003 Outside Directors Stock Plan (“2003 Plan”):

 

 Schedule of Stock Options Roll Forward

   Shares  

Weighted Average

Exercise

Price

  

Weighted Average Remaining Contractual Term

(years)

  

Aggregate Intrinsic

Value (3)

 
Options outstanding January 1, 2022   1,019,400   $4.91          
Granted      $           
Exercised      $         $  
Forfeited/expired      $            
Options outstanding end of period (1)  1,019,400   $4.91    3.8   $1,150,167 
Options exercisable at March 31, 2022(1)  455,900   $3.92    2.5   $779,362 

 

   Shares  

Weighted Average

Exercise

Price

  

Weighted Average Remaining Contractual Term

(years)

  

Aggregate Intrinsic

Value (3)

 
Options outstanding January 1, 2021   658,400   $3.87          
Granted                  
Exercised               $ 
Forfeited/expired                  
Options outstanding end of period (2)  658,400   $3.87    3.2   $2,279,267 
Options exercisable at March 31, 2021(2)  392,400   $4.08    3.4   $1,274,287 

 

(1) Options with exercise prices ranging from $2.79 to $7.50
(2) Options with exercise prices ranging from $2.79 to $7.29
(3) The intrinsic value of a stock option is the amount by which the market value of the underlying stock exceeds the exercise price of the option.

 

During the three months ended March 31, 2022, the Company issued a total of 19,520 shares of its Common Stock under the 2003 Plan to its outside directors as compensation for serving on our Board. The Company recorded approximately $120,000 in compensation expenses (included in selling, general and administration (“SG&A”) expenses) in connection with the issuance of shares of its Common Stock to outside directors.

 

In connection with a $2,500,000 loan that the Company entered into with Mr. Robert Ferguson (the “Ferguson Loan”) on April 1, 2019, the Company issued a warrant to Mr. Ferguson for the purchase of up to 60,000 shares of our Common Stock at an exercise price of $3.51 per share. The warrant expires on April 1, 2024 and remains outstanding at March 31, 2022. The Ferguson Loan was paid-in-full in December 2020.

 

13
 

 

7. Loss Per Share

 

Basic loss per share is calculated based on the weighted-average number of outstanding common shares during the applicable period. Diluted loss per share is based on the weighted-average number of outstanding common shares plus the weighted-average number of potential outstanding common shares. In periods where they are anti-dilutive, such amounts are excluded from the calculations of dilutive loss earnings per shares. The following table reconciles the loss and average share amounts used to compute both basic and diluted loss per share:

 

Schedule of Earning Per Share

     2022 2021 
   Three Months Ended 
   (Unaudited) 
   March 31, 
(Amounts in Thousands, Except for Per Share Amounts)  2022   2021 
Net loss attributable to Perma-Fix Environmental Services, Inc., common stockholders:          
Loss from continuing operations, net of taxes  $(1,249)  $(1,038)
Net loss attributable to non-controlling interest       (30)
Loss from continuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders   (1,249)   (1,008)
Loss from discontinuing operations attributable to Perma-Fix Environmental Services, Inc. common stockholders   (94)   (115)
Net loss attributable to Perma-Fix Environmental Services, Inc. common stockholders  $(1,343)  $(1,123)
          
Basic loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders  $(.10)  $(.09)
          
Diluted loss per share attributable to Perma-Fix Environmental Services, Inc. common stockholders  $(.10)  $(.09)
          
Weighted average shares outstanding:          
Basic weighted average shares outstanding   13,234    12,165 
Add: dilutive effect of stock options        
Add: dilutive effect of warrants        
Diluted weighted average shares outstanding   13,234    12,165 
           
Potential shares excluded from above weighted average share calculations due to their anti-dilutive effect include:          
Stock options   405    30 
Warrant        

 

 

8. Long Term Debt

 

Long-term debt consists of the following:

 

Schedule of Long Term Debt

(Amounts in Thousands)  March 31, 2022   December 31, 2021 
Revolving Credit facility dated May 8, 2020, borrowings based upon eligible accounts receivable, subject to monthly borrowing base calculation, balance due on May 15, 2024. Effective interest rate for first quarter of 2022 was 0%. (1)   $   $ 
Term Loan dated May 8, 2020, payable in equal monthly installments of principal, balance due on May 15, 2024. Effective interest rate for the first quarter of 2022 was 4.3%. (1)    840 (2)   954 (2)
Notes Payable to 2023 and 2025, annual interest rate of 5.6% and 9.1%.   35    39 
Total debt   875    993 
Less current portion of long-term debt   384    393 
Long-term debt  $491   $600 

 

(1)Our revolving credit facility is collateralized by our accounts receivable and our term loan is collateralized by our property, plant, and equipment.
(2)Net of debt issuance costs of ($120,000) and ($112,000) at March 31, 2022 and December 31, 2021, respectively.

 

14
 

 

Revolving Credit and Term Loan Agreement

 

The Company entered into a Second Amended and Restated Revolving Credit, Term Loan and Security Agreement, dated May 8, 2020 (“Loan Agreement”), with PNC National Association (“PNC”), acting as agent and lender. The Loan Agreement provides the Company with the following credit facility with a maturity date of March 15, 2024: (a) up to $18,000,000 revolving credit (“revolving credit”) and (b) a term loan (“term loan”) of approximately $1,742,000, requiring monthly installments of $35,547. The maximum that the Company can borrow under the revolving credit is based on a percentage of eligible receivables (as defined) at any one time reduced by outstanding standby letters of credit and borrowing reductions that our lender may impose from time to time. The Loan Agreement, as amended, also provides a capital expenditure line of up to $1,000,000 with advances on the line, subject to certain limitations, permitted for up to twelve months starting May 4, 2021 (the “Borrowing Period”). Only interest is payable on advances during the Borrowing Period. At the end of the Borrowing Period, the total amount advanced under the line will amortize equally based on a five-year amortization schedule with principal payment due monthly plus interest. At the maturity date of the Loan Agreement, as amended, any unpaid principal balance plus interest, if any, will become due. No advance on the capital line has been made as of March 31, 2022.

 

On March 29, 2022, the Company entered into an amendment to its Loan Agreement with its lender which provided, among other things, the following:

 

  waived the Company’s failure to meet the minimum quarterly fixed charge coverage ratio (“FCCR”) requirement for the fourth quarter of 2021;
  removes the quarterly FCCR testing requirement for the first quarter of 2022;
  reinstates the quarterly FCCR testing requirement starting for the second quarter of 2022 and revises the methodology to be used in calculating the FCCR for the quarters ending June 30, 2022, September 30, 2022, and December 31, 2022 (with no change to the minimum 1.15:1 ratio requirement for each quarter);
  requires maintenance of a minimum of $3,000,000 in borrowing availability under the revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and certified to the lender; and
  revises the annual rate used to calculate the Facility Fee (as defined in the Loan Agreement) on the revolving credit, with addition of the capital expenditure line, from 0.375% to 0.500%. Upon meeting the minimum FCCR requirement of 1.15:1 on a twelve months trailing basis, the Facility Fee rate of 0.375% will be reinstated.

 

In connection with the amendment, we paid PNC a fee of $15,000 which is being amortized over the remaining term of the Loan Agreement, as amended, as interest expense-financing fees.

 

Pursuant to the Loan Agreement, as amended, payment of annual rate of interest due on the revolving credit is at prime (3.50% at March 31, 2022) plus 2% or LIBOR plus 3.00% and the term loan and the capital expenditure line at prime plus 2.50% or LIBOR plus 3.50%. Under the LIBOR option of interest payment, a LIBOR floor of 0.75% applies in the event that LIBOR falls below 0.75% at any point in time.

 

The Company may terminate its Loan Agreement, as amended, upon 90 days’ prior written notice upon payment in full of our obligations under the Loan Agreement. The Company has agreed to pay PNC 0.5% of the total financing if it pays off its obligations after May 7, 2021 but prior to or on May 7, 2022. No early termination fee will apply if the Company pays off its obligations under the Loan Agreement after May 7, 2022.

 

At March 31, 2022, the borrowing availability under the Company’s revolving credit was approximately $4,544,000 based on our eligible receivables and includes a reduction in borrowing availability of approximately $3,020,000 from outstanding standby letters of credit.

 

The Company’s credit facility under its Loan Agreement, as amended, with PNC contains certain financial covenants, along with customary representations and warranties. A breach of any of these financial covenants, unless waived by PNC, could result in a default under our credit facility allowing our lender to immediately require the repayment of all outstanding debt under our credit facility and terminate all commitments to extend further credit. The Company was not required to perform testing of the FCCR requirement in the first quarter of 2022 pursuant to the March 29, 2022 amendment as discussed above, otherwise, it met all of its other financial covenant requirements.

 

15
 

 

9. Commitments and Contingencies

 

Hazardous Waste

 

In connection with our waste management services, the Company processes both hazardous and non-hazardous waste, which we transport to our own, or other, facilities for destruction or disposal. As a result of disposing of hazardous substances, in the event any cleanup is required at the disposal site, the Company could be a potentially responsible party for the costs of the cleanup notwithstanding any absence of fault on our part.

 

Legal Matters

 

In the normal course of conducting our business, we are involved in various litigation. We are not a party to any litigation or governmental proceeding which our management believes could result in any judgments or fines against us that could would have a material adverse effect on our financial position, liquidity or results of future operations.

 

Tetra Tech EC, Inc. (“Tetra Tech”)

 

During July 2020, Tetra Tech EC, Inc. (“Tetra Tech”) filed a complaint in the United States District Court for the Northern District of California (the “Court”) against CH2M Hill, Inc. (“CH2M”) and four subcontractors of CH2M, including the Company (“Defendants”). The complaint alleges various claims, including a claim for negligence, negligent misrepresentation, equitable indemnification and related business claims against all defendants related to alleged damages suffered by Tetra Tech in respect of certain draft reports prepared by defendants at the request of the U.S. Navy as part of an investigation and review of certain whistleblower complaints about Tetra Tech’s environmental restoration at the Hunter’s Point Naval Shipyard in San Francisco.

 

CH2M was hired by the Navy in 2016 to review Tetra Tech’s work. CH2M subcontracted with environmental consulting and cleanup firms Battelle Memorial Institute, Cabrera Services, Inc., SC&A, Inc. and the Company to assist with the review, according to the complaint.

 

Our insurance carrier is providing a defense on our behalf in connection with this lawsuit, subject to a $100,000 self-insured retention and the terms and limitations contained in the insurance policy.

 

On January 7, 2021, Defendants’ motion to dismiss the complaint in its entirety was granted without prejudice, with leave to amend. Tetra Tech subsequently filed a First Amended Complaint (“FAC”) and Defendants filed a motion to dismiss Tetra Tech’s FAC (the “Motion”). Tetra Tech filed an opposition to Defendant’s motion to dismiss Tetra Tech’s FAC. Defendants subsequently filed a joint reply to Tetra Tech’s motion in opposition. On January 27, 2022, the Motion was granted in part and denied in part by the Court. Tetra Tech’s claims for: (1) Negligence; (2) Equitable Indemnification/Contribution; and (3) Unfair Business Practices were dismissed. Tetra Tech was given leave to re-assert the Unfair Business Practices claim but chose not to do so, which means that claim is now also dismissed. Tetra Tech’s claims that survived the Motion are: (1) Intentional Interference with Contractual Relations; and (2) Inducing a Breach of Contract. The Company continues to believe it does not have any liability to Tetra Tech.

 

16
 

 

Perma-Fix Canada, Inc. (“PF Canada”)

 

During the fourth quarter of 2021, PF Canada received a Notice of Termination (“NOT”) from Canadian Nuclear Laboratories, LTD. (“CNL”) on a Task Order Agreement (“TOA”) that PF Canada entered into with CNL in May 2019 for remediation work within Ontario, Canada (“Agreement”). The NOT was received after work under the TOA was substantially completed and work under the TOA has since been completed. CNL may terminate the TOA at any time for convenience. As of March 31, 2022, PF Canada has approximately $2,722,000 in unpaid receivables and unbilled costs due from CNL as a result of work performed under the TOA. Additionally, CNL has approximately $1,150,000 in contractual holdback under the TOA that is payable to PF Canada. CNL also established a bond securing approximately $1,900,000 (CAD) to cover certain issue raised in connection with the TOA. Under the TOA, CNL may be entitled to set off certain costs and expenses incurred by CNL in connection with the termination of the TOA, including the bond as discussed above, against amounts owed to PF Canada for work performed by PF Canada or its subcontractors. PF Canada continues to be in discussions with CNL to finalize the amounts due to PF Canada under the TOA and continues to believes these amounts are due and payable.

 

Insurance

 

The Company has a 25-year finite risk insurance policy entered into in June 2003 (“2003 Closure Policy”) with AIG Specialty Insurance Company (“AIG”), which provides financial assurance to the applicable states for our permitted facilities in the event of unforeseen closure. The 2003 Closure Policy, as amended, provides for a maximum allowable coverage of $28,177,000 which includes available capacity to allow for annual inflation and other performance and surety bond requirements. Total coverage under the 2003 Closure Policy, as amended, was $21,047,000 at March 31, 2022. At March 31, 2022 and December 31, 2021, finite risk sinking funds contributed by the Company related to the 2003 Closure Policy which is included in other long term assets on the accompanying Consolidated Balance Sheets totaled $11,482,000 and $11,471,000, respectively, which included interest earned of $2,011,000 and $2,000,000 on the finite risk sinking funds as of March 31, 2022 and December 31, 2021, respectively. Interest income for the three months ended March 31, 2022 and 2021 was approximately $11,000 and $18,000, respectively. If we so elect, AIG is obligated to pay us an amount equal to 100% of the finite risk sinking fund account balance in return for complete release of liability from both us and any applicable regulatory agency using this policy as an instrument to comply with financial assurance requirements.

 

Letter of Credits and Bonding Requirements

 

From time to time, the Company is required to post standby letters of credit and various bonds to support contractual obligations to customers and other obligations, including facility closures. At March 31, 2022, the total amount of standby letters of credit outstanding was approximately $3,020,000 and the total amount of bonds outstanding was approximately $51,295,000.

 

10. Discontinued Operations

 

The Company’s discontinued operations consist of all our subsidiaries included in our previous Industrial Segment which encompasses subsidiaries divested in 2011 and prior and three previously closed locations.

 

The Company’s discontinued operations had net losses of $94,000 (net of tax benefit of $63,000) and $115,000 (net of taxes of $0) for the three months ended March 31, 2022 and 2021. The losses were primarily due to costs incurred in the administration and continued monitoring of our discontinued operations. The Company’s discontinued operations had no revenues for each of the periods noted above.

 

17
 

 

The following table presents the major class of assets of discontinued operations as of March 31, 2022 and December 31, 2021. No assets and liabilities were held for sale at each of the periods noted.

 

 Schedule of Disposal Groups, Including Discontinued Operation Balance Sheet

   March 31,   December 31, 
(Amounts in Thousands)  2022   2021 
Current assets          
Other assets  $27   $15 
Total current assets   27    15 
Long-term assets          
Property, plant and equipment, net (1)   81    81 
Total long-term assets   81    81 
Total assets  $108   $96 
Current liabilities          
Accounts payable  $34   $3 
Accrued expenses and other liabilities   147    154 
Environmental liabilities   621    349 
Total current liabilities   802    506 
Long-term liabilities          
Closure liabilities   153    150 
Environmental liabilities   255    527 
Total long-term liabilities   408    677 
Total liabilities  $1,210   $1,183 

 

(1)net of accumulated depreciation of $10,000 for each period presented.

 

11. Operating Segments

 

In accordance with ASC 280, “Segment Reporting”, the Company defines an operating segment as a business activity: (1) from which we may earn revenue and incur expenses; (2) whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to make decisions about resources to be allocated to the segment and assess its performance; and (3) for which discrete financial information is available.

 

Our reporting segments are defined as below:

 

TREATMENT SEGMENT, which includes:

 

  - nuclear, low-level radioactive, mixed waste (containing both hazardous and low-level radioactive constituents), hazardous and non-hazardous waste treatment, processing and disposal services primarily through four uniquely licensed and permitted treatment and storage facilities; and
  - R&D activities to identify, develop and implement innovative waste processing techniques for problematic waste streams.

 

SERVICES SEGMENT, which includes:

 

  - Technical services, which include:

 

  professional radiological measurement and site survey of large government and commercial installations using advanced methods, technology and engineering;
  integrated Occupational Safety and Health services including industrial hygiene (“IH”) assessments; hazardous materials surveys, e.g., exposure monitoring; lead and asbestos management/abatement oversight; indoor air quality evaluations; health risk and exposure assessments; health & safety plan/program development, compliance auditing and training services; and Occupational Safety and Health Administration (“OSHA”) citation assistance;
  global technical services providing consulting, engineering, project management, waste management, environmental, and decontamination and decommissioning field, technical, and management personnel and services to commercial and government customers; and
  on-site waste management services to commercial and governmental customers.

 

18
 

 

  - Nuclear services, which include:

 

  technology-based services including engineering, decontamination and decommissioning (“D&D”), specialty services and construction, logistics, transportation, processing and disposal;
  remediation of nuclear licensed and federal facilities and the remediation cleanup of nuclear legacy sites. Such services capability includes: project investigation; radiological engineering; partial and total plant D&D; facility decontamination, dismantling, demolition, and planning; site restoration; logistics; transportation; and emergency response; and

 

  - A company owned equipment calibration and maintenance laboratory that services, maintains, calibrates, and sources (i.e., rental) health physics, IH and customized nuclear, environmental, and occupational safety and health (“NEOSH”) instrumentation.

 

The Company’s segment also included the Medical Segment in 2021. As previously discussed, the Company made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of its interest in PFM Poland (which comprised the Medical Segment) in December 2021. The Company’s Medical Segment had not generated any revenue and was involved in the Company’s medical isotope production technology.

 

Our reporting segments exclude our corporate headquarters and our discontinued operations (see “Note 10 – Discontinued Operations”) which do not generate revenues.

 

The table below presents certain financial information of our operating segments for the three months ended March 31, 2022 and 2021 (in thousands):

 

Segment Reporting for the Quarter Ended March 31, 2022

 Schedule of Segment Reporting Information

   Treatment   Services    Segments Total   Corporate(1)   Consolidated Total 
Revenue from external customers  $7,479   $8,436    $15,915   $   $15,915 
Intercompany revenues   111    183     294         
Gross profit   638    998     1,636        1,636 
Research and development   65    14     79    17    96 
Interest income                11    11 
Interest expense   (14)   (1)    (15)   (20)   (35)
Interest expense-financing fees                (13)   (13)
Depreciation and amortization   371    71     442    14    456 
Segment (loss) income before income taxes   (481)   285     (196)   (1,726)   (1,922)
Income tax benefit   (559)   (114)    (673)       (673)
Segment income (loss)   78    399     477    (1,726)   (1,249)
Expenditures for segment assets   296    49     345        345(2)

 

Segment Reporting for the Quarter Ended March 31, 2021

 

   Treatment   Services   Medical   Segments Total   Corporate(1)   Consolidated Total 
Revenue from external customers  $7,495   $15,638   $  $23,133   $   $23,133 
Intercompany revenues   660    7        667         
Gross profit   925    1,431        2,356        2,356 
Research and development   47    13    76    136    14    150 
Interest income                   18    18 
Interest expense   (19)   (8)       (27)   (40)   (67)
Interest expense-financing fees                   (8)   (8)
Depreciation and amortization   310    85        395    5    400 
Segment (loss) income before income taxes   (119)   555    (76)   360    (1,415)   (1,055)
Income tax benefit   (17)           (17)       (17)
Segment (loss) income   (102)   555    (76)   377    (1,415)   (1,038)
Expenditures for segment assets   357    4        361        361(2)

 

(1)Amounts reflect the activity for corporate headquarters not included in the segment information.
   
(2)Net of financed amount of $114,000 and $29,000 for the three months ended March 31, 2022 and 2021, respectively.

 

19
 

 

12. Income Taxes

 

The Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates, to determine its quarterly provision for income taxes.

 

The Company had income tax benefit of approximately $673,000 for continuing operations for the three months ended March 31, 2022 as compared to income tax benefit of approximately $17,000 for continuing operations for the three months ended March 31, 2021. The Company’s effective tax rate was approximately 35.0% and 1.6% for the three months ended March 31, 2022 and the corresponding period of 2021, respectively. The Company’s tax rate for the three months ended March 31, 2022 was impacted by non-deductible expenses and state taxes. The Company’s tax rate for the three months ended March 31, 2021 was impacted by non-deductible expenses, state taxes, and by the Company’s full valuation on its net deferred tax assets which was subsequently released partially in the third quarter of 2021.

 

13. Variable Interest Entities (“VIE”)

 

The Company and Engineering/Remediation Resources Group, Inc. (“ERRG”) previously entered into an unpopulated joint venture agreement for project work bids within the Company’s Services Segment with the joint venture doing business as Perma-Fix ERRG, a general partnership. The Company has a 51% partnership interest in the joint venture and ERRG has a 49% partnership interest in the joint venture.

 

The Company determines whether joint ventures in which it has invested meet the criteria of a VIE at the start of each new venture and when a reconsideration event has occurred. A VIE is a legal entity that satisfies any of the following characteristics: (a) the legal entity does not have sufficient equity investment at risk; (b) the equity investors at risk as a group, lack the characteristics of a controlling financial interest; or (c) the legal entity is structured with disproportionate voting rights.

 

The Company consolidates a VIE if it is determined to be the primary beneficiary of the VIE. The primary beneficiary has both the power to direct the activities of the VIE that most significantly impact the entity’s economic performance and the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE.

 

Based on the Company’s evaluation of Perma-Fix ERRG and related agreements with Perma-Fix ERRG, the Company determined that Perma-Fix ERRG continues to be a VIE in which we are the primary beneficiary. At March 31, 2022, Perma-Fix ERRG had total assets of $122,000 and total liabilities of approximately $122,000 which are all recorded as current.

 

14. Executive Compensation

 

The Company’s Compensation Committee and the Board determined that no performance payment would be made to each executive officer under his 2021 Management Incentive Plan (“MIP”). In lieu of any performance payment to each executive officer under his 2021 MIP and in an attempt to retain the executive officer, on January 20, 2022, the Compensation Committee and the Board determined that the base annual compensation for each executive officer for 2022 is increased by approximately 6.4%, effective January 1, 2022, to offset the cost-of-living increase.

 

On January 20, 2022, the Board and the Compensation Committee also approved individual MIP for the calendar year 2022 for each of our executive officers. Each MIP is effective January 1, 2022 and applicable for year 2022. Each MIP provides guidelines for the calculation of annual cash incentive-based compensation, subject to Compensation Committee oversight and modification. The performance compensation under each of the MIPs is based upon meeting certain of the Company’s separate target objectives during 2022. Assuming each target objective is achieved under the same performance threshold range under each MIP, the total potential target performance compensation payable ranges from 25% to 150% of the 2022 base salary for the CEO ($93,717 to $562,304), 25% to 100% of the 2022 base salary for the CFO ($76,193 to $304,772), 25% to 100% of the 2022 base salary for the EVP of Strategic Initiatives ($63,495 to $253,980), 25% to 100% of the 2022 base salary for the EVP of Nuclear and Technical Services ($76,193 to $304,772) and 25% to 100% ($65,308 to $261,233) of the 2022 base salary for the EVP of Waste Treatment Operations.

 

15. Subsequent Events

 

Management evaluated events occurring subsequent to March 31, 2022 through May 5, 2022, the date these consolidated financial statements were available for issuance, and determined that no material recognizable subsequent events occurred.

 

20

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

Forward-looking Statements

 

Certain statements contained within this report may be deemed “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (collectively, the “Private Securities Litigation Reform Act of 1995”). All statements in this report other than a statement of historical fact are forward-looking statements that are subject to known and unknown risks, uncertainties and other factors, which could cause actual results and performance of the Company to differ materially from such statements. The words “believe,” “expect,” “anticipate,” “intend,” “will,” and similar expressions identify forward-looking statements. Forward-looking statements contained herein relate to, among other things,

 

demand for our services;
reductions in the level of government funding in future years;
reducing operating costs and non-essential expenditures;
ability to meet loan agreement quarterly covenant requirements;
cash flow requirements;
Canadian receivable;
sufficient liquidity to continue business;
future results of operations and liquidity;
effect of economic disruptions on our business;
government funding for our services;
may not have liquidity to repay debt if our lender accelerates payment of our borrowings;
deployment of unit;
manner in which the applicable government will be required to spend funding to remediate various sites;
funding operations;
continued increases in pricing and/or further tightening supply chain;
fund capital expenditures from cash from operations and/or financing;
impact from COVID-19 and impact from other delays;
improvement in waste shipments;
fund remediation expenditures for sites from funds generated internally;
collection of accounts receivables;
compliance with environmental regulations;
potential effect of being a PRP;
potential sites for violations of environmental laws and remediation of our facilities;

 

21

 

 

remediation of material weakness;
future price increases; and
continuation of contracts with federal government.

 

While the Company believes the expectations reflected in such forward-looking statements are reasonable, it can give no assurance such expectations will prove to be correct. There are a variety of factors, which could cause future outcomes to differ materially from those described in this report, including, but not limited to:

 

general economic conditions;
contract bids, including international markets;
material reduction in revenues;
inability to meet PNC covenant requirements;
inability to collect in a timely manner a material amount of receivables;
increased competitive pressures;
inability to maintain and obtain required permits and approvals to conduct operations;
public not accepting our new technology;
inability to develop new and existing technologies in the conduct of operations;
inability to maintain and obtain closure and operating insurance requirements;
inability to retain or renew certain required permits;
discovery of additional contamination or expanded contamination at any of the sites or facilities leased or owned by us or our subsidiaries which would result in a material increase in remediation expenditures;
delays at our third-party disposal site can extend collection of our receivables greater than twelve months;
refusal of third-party disposal sites to accept our waste;
changes in federal, state and local laws and regulations, especially environmental laws and regulations, or in interpretation of such;
requirements to obtain permits for TSD activities or licensing requirements to handle low level radioactive materials are limited or lessened;
potential increases in equipment, maintenance, operating or labor costs;
management retention and development;
financial valuation of intangible assets is substantially more/less than expected;
the requirement to use internally generated funds for purposes not presently anticipated;
inability to continue to be profitable on an annualized basis;
inability of the Company to maintain the listing of its Common Stock on the NASDAQ;
terminations of contracts with government agencies or subcontracts involving government agencies or reduction in amount of waste delivered to the Company under the contracts or subcontracts;
renegotiation of contracts involving government agencies;
federal government’s inability or failure to provide necessary funding to remediate contaminated federal sites;
disposal expense accrual could prove to be inadequate in the event the waste requires re-treatment;
inability to raise capital on commercially reasonable terms;
inability to increase profitable revenue;
impact of the COVID-19;
delays in waste shipments and delay in activities under new contracts;
new governmental regulations;
lender refuses to waive non-compliance or revise our covenant so that we are in compliance;
continued supply chain interruptions;
continued inflationary pressures;
other unanticipated factors; and

risk factors and other factors set forth in “Special Note Regarding Forward-Looking Statements” contained in the Company’s 2021 Form 10-K and the “Forward-Looking Statements” contained in the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” (“MD&A”) of this first quarter 2022 Form 10-Q.

 

22

 

 

COVID-19 Impact and Impact due to Other Delays

 

Our first quarter financial results continued to be impacted by COVID-19. As previously disclosed, within our Services Segment, we experienced delays in procurement actions and contract awards during the first half of 2021 resulting from the impact of COVID-19. Since the end of the second quarter of 2021, we were awarded a number of new contracts. However, due to continued COVID-19 impact and/or customer administrative delay experienced by certain customers, work under certain of our new awards was temporarily curtailed/delayed which continued for most of the first quarter of 2022 and negatively impacted revenue. We have, however, begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. Our Treatment Segment revenue continues to be negatively impacted by continued waste shipment delays from certain customers since the latter part of the first quarter of 2020, the start of the pandemic. We expect to see a gradual improvement in waste receipts from these customers in the upcoming months as our customers start easing up on COVID-19 restrictions; however, such may not be the case based on our customers’ own responses to COVID-19, including, but not limited to delaying or limiting full return-to-work schedules. Additionally, as a result of supply chain challenges, we experienced a delay in the delivery of a new technology waste processing unit from our supplier which negatively impacted our revenue as associated revenue was not able to be generated. Delivery of this unit had been expected during the third quarter of 2021 but did not occur until the latter part of the first quarter of 2022. Deployment of this unit is expected to commence in the second quarter of 2022. Within our Treatment Segment, we are experiencing a large increase in proposal requests. We continue to have bids currently submitted in both segments and awaiting awards.

 

At this time, we believe we have sufficient liquidity on hand to continue business operations during the next twelve months. At March 31, 2022, we had borrowing availability under our revolving credit facility of approximately $4,544,000 which was based on a percentage of eligible receivables and subject to certain reserves. As a result of a recent amendment to our Loan Agreement, we are required to maintain a minimum of $3,000,000 in borrowing availability under our revolving credit until the minimum FCCR requirement for the quarter ended June 30, 2022 has been met and certified to our lender (see “Financing Activities” within this MD&A for a discussion of this amendment). We continue to assess the need in reducing operating costs during this volatile time, which may include curtailing certain capital expenditures and eliminating non-essential expenditures.

 

We are closely monitoring our customers’ payment performance. However, since a significant portion of our revenues is derived from government related contracts, we do not expect our accounts receivable collections to be materially impacted due to COVID-19.

 

As the situations surrounding COVID-19 continues to remain fluid, the full impact and extent of the pandemic on our financial results and liquidity cannot be estimated with any degree of certainty. We continue to closely monitor the impact of the COVID-19 pandemic on all aspects of our business, including supply chain challenges, our labor force and increasing costs from inflationary pressures (see “Known Trends and Uncertainties” – “Supply Chain” and “Inflation and Cost Increases” within this MD&A).

 

23

 

 

Overview

 

Revenue decreased by $7,218,000 or 31.2% to $15,915,000 for the three months ended March 31, 2022 from $23,133,000 for the corresponding period of 2021. The decrease was primarily within our Services Segment where revenue decreased to $8,436,000 from $15,638,000 or approximately 46.1%. As discussed above, work under certain of the new projects awarded to our Services Segment at the end of the second quarter of 2021 continued to be delayed/curtailed for most of the first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. The lower revenue in the first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the completion of a large project in the second quarter of 2021 which was not replaced with a similar size contract because of delays in contract awards and procurement from COVID-19 impact in the first half of 2021. Our Treatment Segment revenue decreased slightly by $16,000 or 0.2%. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has not returned to pre-pandemic levels as certain customers continue to delay waste shipments due to impact of COVID-19. Gross profit decreased $720,000 or 30.6%. Selling, General, and Administrative (“SG&A”) expenses increased $217,000 or 6.8% for the three months ended March 31, 2022 as compared to the corresponding period of 2021.

 

Business Environment

 

Our Treatment and Services Segments’ business continues to be heavily dependent on services that we provide to governmental clients, primarily as subcontractors for others who are prime contractors to government entities or directly as the prime contractor. We believe demand for our services will continue to be subject to fluctuations due to a variety of factors beyond our control, including, without limitation, the economic conditions, the manner in which the applicable government will be required to spend funding to remediate various sites, and/or potential further impact from COVID-19. In addition, our governmental contracts and subcontracts relating to activities at governmental sites in the United States are generally subject to termination for convenience at any time at the government’s option, and our governmental contracts/task orders with the Canadian government authorities also allow the authorities to terminate the contract/task orders at any time for convenience. Our work under all of our contracts/task order agreements with Canadian government authorities has substantially been completed. See “Known Trends and Uncertainties – Perma-Fix Canada, Inc. (“PF Canada”)” for additional discussion as to a terminated Canadian TOA. Significant reductions in the level of governmental funding or specifically mandated levels for different programs that are important to our business could have a material adverse impact on our business, financial position, results of operations and cash flows.

 

We are continually reviewing methods to raise additional capital to supplement our liquidity requirements, when needed, and reducing our operating costs. We continue to aggressively bid on various contracts, including potential contracts within the international markets.

 

Results of Operations

 

The reporting of financial results and pertinent discussions are tailored to our two reportable segments: The Treatment and Services. Our financial results for 2021 also included our Medical Segments. As previously disclosed, we made the strategic decision to cease all R&D activities under the Medical Segment and sold 100% of our interest in PFM Poland (which comprised the Medical Segment) in December 2021. Our Medical Segment had not generated any revenue and was involved in our medical isotope production technology. All costs previously incurred by the Medical Segment were included within R&D.

 

24

 

 

Summary – Three Months Ended March 31, 2022 and 2021

 

   Three Months Ended
   March 31,
Consolidated (amounts in thousands)  2022   %   2021   % 
Revenues  $15,915    100.0   $23,133    100.0 
Cost of good sold   14,279    89.7    20,777    89.8 
Gross profit   1,636    10.3    2,356    10.2 
Selling, general and administrative   3,422    21.5    3,205    13.9 
Research and development   96    .6    150    .6 
Loss on disposal of property and equipment   1     —     —     — 
Loss from operations  $(1,883)   (11.8)  $(999)   (4.3)
Interest income   11     —    18     — 
Interest expense   (35)   (.2)   (67)   (.2)
Interest expense-financing fees   (13)   (.1)   (8)    — 
Other   (2)       1     — 
Loss from continuing operations before taxes   (1,922)   (12.1)   (1,055)   (4.5)
Income tax benefit   (673)   (4.3)   (17)    — 
Loss from continuing operations  $(1,249)   (7.8)  $(1,038)   (4.5)

 

Revenues

 

Consolidated revenues decreased $7,218,000 for the three months ended March 31, 2022, compared to the three months ended March 31, 2021, as follows:

 

(In thousands)  2022   % Revenue   2021   % Revenue   Change   % Change 
Treatment                              
Government waste  $5,437    34.2   $4,387    18.9   $1,050    23.9 
Hazardous/non-hazardous (1)   1,001    6.3    1,311    5.7    (310)   (23.6)
Other nuclear waste   1,041    6.5    1,797    7.8    (756)   (42.1)
Total   7,479    47.0    7,495    32.4    (16)   (0.2)
                               
Services                              
Nuclear services   8,281    52.0    15,080    65.2    (6,799)   (45.1)
Technical services   155    1.0    558    2.4    (403)   (72.2)
Total   8,436    53.0    15,638    67.6    (7,202)   (46.1)
                               
Total  $15,915    100.0   $23,133    100.0   $(7,218)   (31.2)

 

(1) Includes wastes generated by government clients of $470,000 and $745,000 for the three months ended March 31, 2022 and the corresponding period of 2021, respectively.

 

Treatment Segment revenue decreased slightly by $16,000 or 0.2% for the three months ended March 31, 2022 over the same period in 2021. The decrease in hazardous/non-hazardous revenue was primarily due to lower waste volume. Revenue from other nuclear waste was lower primarily due to lower averaged price waste. Waste from government generators increased by approximately $1,050,000 or 23.9% primarily due higher waste volume. Although we saw minimal overall change in revenue within Treatment Segment, our Treatment Segment revenue has not returned to pre-pandemic levels as certain customers continue to delay waste shipments due, in part, to impact of COVID-19. Our Services Segment revenue decreased by approximately $7,202,000 or 46.1%. Work under certain of the new projects awarded to our Services Segment at the end of the second quarter of 2021 continued to be delayed/curtailed for most of the first quarter of 2022 due to COVID-19 impact and/or administrative delays experienced by certain customers. However, we have begun to see improvement in activities from certain of these new projects starting in the latter part of the first quarter of 2022. The lower revenue in the first quarter of 2022 resulting from delays/curtailments in work was further exacerbated by the completion of a large project in the second quarter of 2021 which was not replaced with a similar size contract from delays in contract awards and procurement from COVID-19 impact in the first half of 2021. Our Services Segment revenues are project based; as such, the scope, duration and completion of each project vary. As a result, our Services Segment revenues are subject to differences relating to timing and project value.

 

25

 

 

Cost of Goods Sold

 

Cost of goods sold decreased $6,498,000 for the quarter ended March 31, 2022, compared to the quarter ended March 31, 2021, as follows:

 

       %       %     
(In thousands)  2022   Revenue   2021   Revenue   Change 
Treatment  $6,841    91.5   $6,570    87.7   $271 
Services   7,438    88.2    14,207    90.8    (6,769)
Total  $14,279    89.7   $20,777    89.8   $(6,498)

 

Cost of goods sold for the Treatment Segment increased by approximately $271,000 or 4.1%. The increased costs was primarily due to higher overall fixed costs of approximately $277,000 resulting from the following: general expenses were higher by $144,000 primarily due to higher utility costs; salaries and payroll related expenses were higher by approximately $49,000; depreciation expenses were higher by approximately $59,000 due to depreciation for asset retirement obligations in connection with our EWOC facility; regulatory expenses were higher by approximately $15,000; and travel expenses were higher by $10,000 resulting from easing up of COVID-19 restrictions. Treatment Segment’s variable costs decreased slightly by approximately $6,000 primarily due to lower overall costs in disposal, transportation, material and supplies which were mostly offset by higher outside services costs. Services Segment cost of goods sold decreased approximately $6,769,000 or 47.6% primarily due to lower revenue. The decrease in cost of goods sold was primarily due to lower salaries/payroll related, travel, and outside services expenses totaling $6,909,000. The overall lower costs were partially offset by higher material and supplies costs. Included within cost of goods sold is depreciation and amortization expense of $439,000 and $394,000 for the three months ended March 31, 2022, and 2021, respectively.

 

Gross Profit

 

Gross profit for the quarter ended March 31, 2022 decreased $720,000 over the corresponding period of 2021, as follows:

 

       %       %     
(In thousands)  2022   Revenue   2021   Revenue   Change 
Treatment  $638    8.5   $925    12.3   $(287)
Services   998    11.8    1,431    9.2    (433)
Total  $1,636    10.3   $2,356    10.2   $(720)

 

Treatment Segment gross profit decreased by $287,000 or 31.0% and gross margin decreased to 8.5% from 12.3% primarily due to the impact of our fixed costs. Services Segment gross profit decreased by $433,000 or 30.3% and gross margin increased from 9.2% to 11.8%. Our overall Services Segment gross margin is impacted by our current projects which are competitively bid on and will therefore, have varying margin structures.

 

SG&A

 

SG&A expenses increased $217,000 for the three months ended March 31, 2022, as compared to the corresponding period for 2021, as follows:

 

(In thousands)  2022   % Revenue   2021   % Revenue   Change 
Administrative  $1,687     —   $1,372     —   $315 
Treatment   1,040    13.9    978    13.0    62